OpenGate Capital Fully Exits Investment in EverZinc
OpenGate Capital, a global private equity firm, announced that it has exited its investment in EverZinc, a global provider of specialty zinc materials, through a sale to U.S. Zinc, a portfolio company of Aterian Investment Partners. Terms of the investment were not disclosed.
EverZinc is headquartered in Liège, Belgium and has industrial operations in Belgium, Canada, the Netherlands, Norway, China, and Malaysia. EverZinc specializes in four product lines: fine zinc powders, zinc oxide, zinc for batteries, and Zano®, an ultra-fine zinc oxide. EverZinc products are sold to customers around the world for use in a variety of applications, including anti-corrosion paints, tires, pharmaceutical chemicals, ceramics and glass, and sunscreens.
The business is led by CEO, Vincent Dujardin, and was acquired by OpenGate Capital in 2016 through a corporate carve-out from Umicore. During OpenGate’s ownership, EverZinc grew EBITDA by 2x, and expanded its product mix and geographic footprint, all while further strengthening its ESG attributes.
Julien Lagrèze, OpenGate Partner and Head of Europe, commented on the transaction, stating, “When we acquired EverZinc, we believed the business had tremendous potential for geographic expansion and innovation, and, under Vincent’s leadership, new products were developed and new markets penetrated, which re-positioned the company for growth and enhanced profitability. It has been a truly rewarding experience working with Vincent and his team, and we’re confident that EverZinc is in great hands as it embarks on a new phase of growth.”
EverZinc will join U.S. Zinc, a global zinc chemistry and material science business, manufacturing diversified zinc products including zinc oxide, zinc powder, and zinc metal used in end markets such as tires, chemicals, coatings, and agriculture.
Commenting on the sale, Dujardin stated, “I am incredibly proud of leading EverZinc, which is an innovative, diverse, and global business that is supported by an incredibly dedicated team of people. I am confident that the business will have much success with U.S. Zinc.”
Jefferies served as lead financial advisor and Stifel served as financial advisor to OpenGate Capital.
About OpenGate Capital
OpenGate Capital is a global private equity firm specializing in the acquisition and operation of businesses to create new value through operational improvements, innovation, and growth. Established in 2005, OpenGate Capital is headquartered in Los Angeles, California with a European office in Paris, France. OpenGate’s professionals possess the critical skills needed to acquire, transition, operate, build, and scale successful businesses. To date, OpenGate Capital has executed 40 acquisitions across North America and Europe. To learn more about OpenGate, please visit www.opengatecapital.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220601005187/en/
Contact information
OpenGate Media Contacts
Prosek Partners
Email: Pro-opengate@prosek.com
Alanna Chaffin
Co-Head, Investor Relations & Communications
Email: AChaffin@opengatecapital.com
Telephone: +1 310-432-7000
OpenGate Business Development Contact
Joshua Adams
Email: jadams@opengatecapital.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines to Present at Upcoming Investor Conferences28.10.2025 12:01:00 EET | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in fireside chats at two upcoming investor conferences: Guggenheim Second Annual Healthcare Innovation Conference on Monday, November 10, 2025 at 9:30 am EST; and Jefferies Global Healthcare Conference in London on Monday, November 17, 2025 at 4:00 pm GMT/11:00 am EST Live webcasts of these events can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com, https://hkexir.beonemedicines.com, https://sseir.beonemedicines.com. Archived replays will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through
Allianz Reports Safety Gains From Automated Mobility and Urges EU-Wide “Driving License” for Autonomous Vehicles28.10.2025 11:05:00 EET | Press release
The promise of autonomous mobility is not just a technological leap – it represents a transformation in safety, comfort, and accessibility that is already underway with Level 3 vehicles on European roads and Level 4 systems operating in real-world test fields. At the 13th Allianz Motor Day in 2025, hosted by the Allianz Center for Technology (AZT), Allianz unveiled significant safety gains from autonomous vehicles and calls for EU-wide testing standards to ensure their safe integration into European roads, including questions about vehicle safety, liability, the use of in-vehicle data from autonomous vehicles (AVs), and more inclusive mobility. The company already insures test fields in several countries, including Germany, Norway, and Singapore. AZT research and proprietary claims analysis indicate a significant decline in motor liability claims frequency driven by advanced driver assistance systems (ADAS) now available in select models. While these systems already demonstrate impress
Ares Management and Slate Asset Management to Acquire Polish Real Estate Portfolio Valued at Over €300 Million From Trei Real Estate28.10.2025 10:15:00 EET | Press release
Ares Management Corporation (“Ares”) (NYSE: ARES), a leading global alternative investment manager, and Slate Asset Management (“Slate”), a global investor and manager focused on essential real estate and infrastructure, today announced that a joint venture between Ares Real Estate funds (“Ares Real Estate”) and Slate has agreed to acquire a portfolio of 36 properties in Poland (the “Portfolio”) from Trei Real Estate, an internationally active developer and asset manager. The Portfolio is valued at over €300 million. The Portfolio comprises 36 recently developed and fully occupied convenience-led retail parks strategically located across major Polish metropolitan areas near large catchment populations. The assets are inflation-protected through CPI-linked lease agreements underpinned by tenants with strong covenants. Most of the Portfolio’s income is derived from large regional retailers and essential goods providers, including grocers and pharmacies. “This transaction underlines our c
SK pharmteco Achieves Highest-Level My Green Lab Certifications Across Europe and Asia28.10.2025 10:00:00 EET | Press release
SK pharmteco, a global contract development and manufacturing organization (CDMO), today announced a significant milestone in its commitment to environmental sustainability by earning four My Green Lab certifications, including two at the program’s highest level, Green. The remaining two labs earned Gold certification, reflecting advanced sustainability performance and progression toward full Green maturity. The certified facilities are Small Molecule Europe (Swords, Ireland) and Small Molecule Asia (Daejeon, South Korea), and the certifications cover the areas of Quality Control, Process Research & Development, and Analytical Research & Development. My Green Lab certification is widely regarded as the global standard for laboratory sustainability, recognized by the United Nations Race to Zero campaign for its rigor in advancing credible decarbonization. Green certification is the program’s highest designation, reserved for laboratories that demonstrate exceptional, independently verif
Kemwell Biopharma Facility in Bengaluru Successfully Completes U.S. FDA Inspection for Commercial Drug-Product Manufacturing28.10.2025 08:00:00 EET | Press release
Kemwell Biopharma Pvt Ltd (“Kemwell”), a leading global biologics Contract Development and Manufacturing Organization (CDMO), announced today that its drug-product manufacturing facility in Bengaluru has successfully completed a U.S. Food and Drug Administration (FDA) pre-approval inspection (PAI) and is now cleared for the commercial manufacturing and testing of injectable products destined for the U.S. market. This milestone marks the approval of the first product to get U.S. FDA clearance for commercial supply from Kemwell’s Bengaluru drug-product facility since the site became a dedicated biologics campus eight years ago. It demonstrates the company’s ability to meet stringent current Good Manufacturing Practice (cGMP) and aseptic drug-product manufacturing standards. “Achieving FDA clearance for commercial manufacturing from our Bengaluru site marks a defining moment in Kemwell’s growth journey,” said Anurag Bagaria, Chairman and CEO, Kemwell Biopharma. “It reflects our team’s ste
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom